stars 1 stars 2 stars 3

At Creyon, we are redefining what’s possible in RNA drug design. Creyon is an AI-driven drug development company creating tissue-specific, RNA-targeted nucleic acid therapies that are designed to be safer, more effective, and easier for patients to stay on. Our focus is on conditions where current RNA therapies face barriers to delivery and tolerability, including neuromuscular, central nervous system (CNS), and immunology disorders. Our mission is to unlock the full therapeutic potential of RNA medicines through intelligent design, precise delivery, and a deep understanding of tissue biology enabling better outcomes and improved quality of life for patients. Our vision is that the next generation of RNA medicines will be tissue-aware, computationally designed, and patient-centered, and we plan to lead that transformation bringing precision, predictability, and accessibility to RNA drug development.

Creyon Bio Questions

The Creyon Bio annual revenue was $5.5 million in 2026.

Matthew Levy is the SVP, Head of Research of Creyon Bio.

15 people are employed at Creyon Bio.

Creyon Bio is based in San Diego, California.

Top Creyon Bio Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users